Robert Jablonka

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

José M. Gatell, Lambert Assoumou, Graeme Moyle et al. · Clinical Infectious Diseases · 2018 · 48 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Substance use and sexual risk behaviour among <scp>HIV</scp>‐positive men who have sex with men in specialized out‐patient clinics

Henrike Dirks, R. Borgmann, Manfred Wolter et al. · HIV Medicine · 2012 · 41 citations

Medicine, Health Behavior, Hiv Prevention +10

Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

Ana Gonzalez‐Cordón, Lambert Assoumou, Graeme Moyle et al. · Journal of Antimicrobial Chemotherapy · 2021 · 27 citations · Full text

Veterinary Medicine, Pharmacology, Pharmacotherapy +17

HIV-1 persistent viremia is frequently followed by episodes of low-level viremia

Marek Widera, Miriam Dirks, Barbara Bleekmann et al. · Medical Microbiology and Immunology · 2017 · 19 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial

Laura Waters, Lambert Assoumou, Ana Gonzalez‐Cordón et al. · Clinical Infectious Diseases · 2022 · 17 citations · Full text

Pharmacy, Pharmacotherapy, Clinical Nutrition +16